Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EnvDNA + PolyEnv1 + EnvPro
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
EnvDNA + PolyEnv1 + EnvPro is a combination investigational HIV vaccine regimen designed as a multi-envelope, prime-boost strategy. The regimen consists of three components: - **EnvDNA** (a DNA-based vaccine encoding HIV envelope proteins) - **PolyEnv1** (a polyvalent vaccinia virus vector expressing multiple HIV-1 envelope antigens) - **EnvPro** (a recombinant protein component containing HIV envelope proteins) This combination aims to stimulate both cellular and humoral immune responses against diverse strains of HIV by sequentially priming and boosting the immune system with different forms of the viral envelope antigen. The approach is intended to enhance immunogenicity compared to single-component vaccines. Developed primarily for prophylactic use in preventing HIV infection, this regimen has been evaluated in early-phase clinical trials for safety and immunogenicity[1][2][3][7].
02
Targets
gp120 (HIV-1 envelope glycoprotein (gp120/gp41) epitopes)
Beyond the preview
Go deeper on EnvDNA + PolyEnv1 + EnvPro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EnvDNA + PolyEnv1 + EnvPro.